AI

Organizations have used geospatial machine learning (ML) for property risk assessment, disaster response, and infrastructure planning. These systems worked well but couldn’t scale beyond specialized use cases. Each question required multiple geospatial datasets, each with its own model and often its own workflow, limiting these capabilities to a handful of high-value use cases at the […]

This post is co-written with Rejin Surendran from Wipro Enterprises Limited and Bakrudeen K from ShellKode. In manufacturing environments, industrial automation engineers face a significant challenge: how to rapidly convert complex process requirements into Programmable Logic Controller (PLC) ladder text code. This traditional, manual process typically requires 3-4 days per query, creating bottlenecks in production

As Nvidia, OpenAI, Google, and Microsoft forge partnerships and deals, the AI industry is looking more like one interconnected machine. What does that mean for all of us?

Apple Shortcuts, which lets users write custom automations, recently earned some new capabilities thanks to Apple Intelligence. Here,s how to make the most of this upgrade.

Leading the Future said it will spend millions to keep Alex Bores out of Congress. It might be helping him instead.

I used the public preview of Fitbit’s new AI Health Coach and became both faster and noticeably weirder.

Google’s latest AI image model is vastly better than the previous release at generating text in images. You can expect companies to go buck wild with this update.

A federal prosecutor alleged that one defendant boasted that his father “had engaged in similar business for the Chinese Communist Party.”

This post is co-written with Hossein Salami and Jwalant Vyas from MSD.  In the biopharmaceutical industry, deviations in the manufacturing process are rigorously addressed. Each deviation is thoroughly documented, and its various aspects and potential impacts are closely examined to help ensure drug product quality, patient safety, and compliance. For leading pharmaceutical companies, managing these

Genomic research stands at a transformative crossroads where the exponential growth of sequencing data demands equally sophisticated analytical capabilities. According to the 1000 Genomes Project, a typical human genome differs from the reference at 4.1–5.0 million sites, with most variants being SNPs and short indels. These variants, when aggregated across individuals, contribute to differences in